These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 33955591)

  • 21. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery.
    Roug AS; Hokland LB; Segel E; Nielsen K; Toft-Petersen M; Van Kooten Niekerk PB; Hokland P; Nederby L
    Cytotherapy; 2014 Mar; 16(3):392-401. PubMed ID: 24424268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful mobilization of PBSCs predicts favorable outcomes in multiple myeloma patients treated with novel agents and autologous transplantation.
    Brioli A; Perrone G; Patriarca F; Pezzi A; Nobile F; Ballerini F; Motta MR; Ronconi S; Tacchetti P; Catalano L; Zannetti BA; Rizzi S; Volpe S; Zamagni E; Liberati AM; Mancuso K; Boccadoro M; Davies FE; Morgan GJ; Palumbo A; Cavo M
    Bone Marrow Transplant; 2015 May; 50(5):673-8. PubMed ID: 25642764
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
    Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.
    Nair AP; Walker P; Kalff A; Bergin K; Hocking J; Avery S; Curtis DJ; Patil S; Das T; Klarica D; Morgan S; Muirhead J; Gorniak M; Reynolds J; Spencer A
    Bone Marrow Transplant; 2017 Jun; 52(6):839-845. PubMed ID: 28319080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?
    Singh V; Krishnamurthy J; Duffey S; Meagher R; Villa M; Monreal J; Evens A; Frankfurt O; Altman J; Gordon L; Tallman M; Williams S; Winter J; Singhal S; Mehta J
    Bone Marrow Transplant; 2009 Feb; 43(4):301-5. PubMed ID: 18836491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of CD34-selected and CD19-depleted autografting in multiple myeloma patients: a pilot study.
    Rasmussen T; Björkstrand B; Andersen H; Gaarsdal E; Johnsen HE
    Exp Hematol; 2002 Jan; 30(1):82-8. PubMed ID: 11823041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma.
    Vescio R; Schiller G; Stewart AK; Ballester O; Noga S; Rugo H; Freytes C; Stadtmauer E; Tarantolo S; Sahebi F; Stiff P; Meharchard J; Schlossman R; Brown R; Tully H; Benyunes M; Jacobs C; Berenson R; DiPersio J; Anderson K; Berenson J
    Blood; 1999 Mar; 93(6):1858-68. PubMed ID: 10068658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution.
    Michallet M; Philip T; Philip I; Godinot H; Sebban C; Salles G; Thiebaut A; Biron P; Lopez F; Mazars P; Roubi N; Leemhuis T; Hanania E; Reading C; Fine G; Atkinson K; Juttner C; Coiffier B; Fière D; Archimbaud E
    Exp Hematol; 2000 Jul; 28(7):858-70. PubMed ID: 10907648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group.
    Waszczuk-Gajda A; Drozd-Sokołowska J; Boguradzki P; Dybko J; Wróbel T; Basak GW; Mądry K; Snarski E; Charliński G; Frączak E; Matuszkiewicz-Rowińska J; Klinger M; Augustyniak-Bartosik H; Krajewska M; Żebrowski P; Król M; Urbanowska E; Jurczyszyn A; Taszner M; Jędrzejczak WW; Dwilewicz-Trojaczek J
    J Clin Apher; 2018 Jun; 33(3):249-258. PubMed ID: 28922455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure.
    Worel N; Fritsch G; Agis H; Böhm A; Engelich G; Leitner GC; Geissler K; Gleixner K; Kalhs P; Buxhofer-Ausch V; Keil F; Kopetzky G; Mayr V; Rabitsch W; Reisner R; Rosskopf K; Ruckser R; Zoghlami C; Zojer N; Greinix HT
    J Clin Apher; 2017 Aug; 32(4):224-234. PubMed ID: 27578390
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune reconstitution after transplantation of autologous peripheral CD34+ cells: analysis of predictive factors and comparison with unselected progenitor transplants.
    Rutella S; Rumi C; Laurenti L; Pierelli L; Sora' F; Sica S; Leone G
    Br J Haematol; 2000 Jan; 108(1):105-15. PubMed ID: 10651733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograft-Allograft in Multiple Myeloma.
    Giaccone L; Evangelista A; Patriarca F; Sorasio R; Pini M; Carnevale-Schianca F; Festuccia M; Brunello L; Zallio F; Maffini E; Omedé P; Bringhen S; Mordini N; Fanin R; Ciccone G; Boccadoro M; Bruno B
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):189-193. PubMed ID: 28987930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
    Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study.
    Lemoli RM; Martinelli G; Olivieri A; Motta MR; Rizzi S; Terragna C; Leopardi G; Benni M; Ronconi S; Cantori I; Rondelli D; Mangianti S; Leoni P; Montanari M; Cavo M; Tura S
    Br J Haematol; 1999 Nov; 107(2):419-28. PubMed ID: 10583236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.